These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 31462329)

  • 1. Deletion at 2q14.3 is associated with worse response to TNF-α blockers in patients with rheumatoid arthritis.
    Gu KN; Bang SY; Lee HS; Park Y; Kang JY; Kim JS; Nam B; Yoo HS; Shin JM; Lee YK; Lee TH; Chun S; Cho SK; Choi CB; Sung YK; Kim TH; Jun JB; Yoo DH; Kim K; Bae SC
    Arthritis Res Ther; 2019 Aug; 21(1):195. PubMed ID: 31462329
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Are there any positive effects of TNF-alpha blockers on bone metabolism?].
    Seriolo B; Paolino S; Sulli A; Cutolo M
    Reumatismo; 2006; 58(3):199-205. PubMed ID: 17013436
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of polymorphisms in TRAILR1 and TNFR1A on the response to anti-TNF therapies in patients with rheumatoid and psoriatic arthritis.
    Morales-Lara MJ; Cañete JD; Torres-Moreno D; Hernández MV; Pedrero F; Celis R; García-Simón MS; Conesa-Zamora P
    Joint Bone Spine; 2012 Dec; 79(6):591-6. PubMed ID: 22480748
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Associations between PTPRC rs10919563 A/G and FCGR2A R131H polymorphisms and responsiveness to TNF blockers in rheumatoid arthritis: a meta-analysis.
    Lee YH; Bae SC
    Rheumatol Int; 2016 Jun; 36(6):837-44. PubMed ID: 27074847
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Associations between tumor necrosis factor-alpha (TNF-alpha) -308 and -238 G/A polymorphisms and shared epitope status and responsiveness to TNF-alpha blockers in rheumatoid arthritis: a metaanalysis update.
    Lee YH; Ji JD; Bae SC; Song GG
    J Rheumatol; 2010 Apr; 37(4):740-6. PubMed ID: 20194454
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Variations in the metabolome in response to disease activity of rheumatoid arthritis.
    Tatar Z; Migne C; Petera M; Gaudin P; Lequerre T; Marotte H; Tebib J; Pujos Guillot E; Soubrier M
    BMC Musculoskelet Disord; 2016 Aug; 17(1):353. PubMed ID: 27549132
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A longitudinal genome-wide association study of anti-tumor necrosis factor response among Japanese patients with rheumatoid arthritis.
    Honne K; Hallgrímsdóttir I; Wu C; Sebro R; Jewell NP; Sakurai T; Iwamoto M; Minota S; Jawaheer D
    Arthritis Res Ther; 2016 Jan; 18():12. PubMed ID: 26776603
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Etanercept, infliximab, and leflunomide in established rheumatoid arthritis: clinical experience using a structured follow up programme in southern Sweden.
    Geborek P; Crnkic M; Petersson IF; Saxne T;
    Ann Rheum Dis; 2002 Sep; 61(9):793-8. PubMed ID: 12176803
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A Combined Transcriptomic and Genomic Analysis Identifies a Gene Signature Associated With the Response to Anti-TNF Therapy in Rheumatoid Arthritis.
    Aterido A; Cañete JD; Tornero J; Blanco F; Fernández-Gutierrez B; Pérez C; Alperi-López M; Olivè A; Corominas H; Martínez-Taboada V; González I; Fernández-Nebro A; Erra A; López-Lasanta M; López Corbeto M; Palau N; Marsal S; Julià A
    Front Immunol; 2019; 10():1459. PubMed ID: 31312201
    [No Abstract]   [Full Text] [Related]  

  • 10. Genotype at the sIL-6R A358C polymorphism does not influence response to anti-TNF therapy in patients with rheumatoid arthritis.
    Hassan B; Maxwell JR; Hyrich KL; ; Barton A; Worthington J; Isaacs JD; Morgan AW; Wilson AG
    Rheumatology (Oxford); 2010 Jan; 49(1):43-7. PubMed ID: 19926672
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register.
    Hyrich KL; Watson KD; Silman AJ; Symmons DP;
    Rheumatology (Oxford); 2006 Dec; 45(12):1558-65. PubMed ID: 16705046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis.
    Seriolo B; Paolino S; Sulli A; Ferretti V; Cutolo M
    Ann N Y Acad Sci; 2006 Jun; 1069():420-7. PubMed ID: 16855169
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A systematic review of the effectiveness of adalimumab, etanercept and infliximab for the treatment of rheumatoid arthritis in adults and an economic evaluation of their cost-effectiveness.
    Chen YF; Jobanputra P; Barton P; Jowett S; Bryan S; Clark W; Fry-Smith A; Burls A
    Health Technol Assess; 2006 Nov; 10(42):iii-iv, xi-xiii, 1-229. PubMed ID: 17049139
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-world Effectiveness of Biologic Disease-modifying Antirheumatic Drugs for the Treatment of Rheumatoid Arthritis After Etanercept Discontinuation in the United Kingdom, France, and Germany.
    Li N; Betts KA; Messali AJ; Skup M; Garg V
    Clin Ther; 2017 Aug; 39(8):1618-1627. PubMed ID: 28729087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis.
    Maxwell JR; Potter C; Hyrich KL; ; Barton A; Worthington J; Isaacs JD; Morgan AW; Wilson AG
    Hum Mol Genet; 2008 Nov; 17(22):3532-8. PubMed ID: 18713756
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Etanercept decreases synovial expression of tumour necrosis factor-α and lymphotoxin-α in rheumatoid arthritis.
    Neregård P; Krishnamurthy A; Revu S; Engström M; af Klint E; Catrina AI
    Scand J Rheumatol; 2014; 43(2):85-90. PubMed ID: 24313444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lipid profile of rheumatoid arthritis patients treated with anti-tumor necrosis factor-alpha drugs changes according to disease activity and predicts clinical response.
    Cacciapaglia F; Anelli MG; Rinaldi A; Serafino L; Covelli M; Scioscia C; Iannone F; Lapadula G
    Drug Dev Res; 2014 Nov; 75 Suppl 1():S77-80. PubMed ID: 25381986
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fcgamma receptor type IIIA genotype and response to tumor necrosis factor alpha-blocking agents in patients with rheumatoid arthritis.
    Kastbom A; Bratt J; Ernestam S; Lampa J; Padyukov L; Söderkvist P; Skogh T
    Arthritis Rheum; 2007 Feb; 56(2):448-52. PubMed ID: 17265480
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Anti-nuclear antibodies, anti-DNA and C4 complement evolution in rheumatoid arthritis and ankylosing spondylitis treated with TNF-alpha blockers.
    Gonnet-Gracia C; Barnetche T; Richez C; Blanco P; Dehais J; Schaeverbeke T
    Clin Exp Rheumatol; 2008; 26(3):401-7. PubMed ID: 18578960
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association of TNF-alpha -308 G/A polymorphism with responsiveness to TNF-alpha-blockers in rheumatoid arthritis: a meta-analysis.
    Lee YH; Rho YH; Choi SJ; Ji JD; Song GG
    Rheumatol Int; 2006 Dec; 27(2):157-61. PubMed ID: 16909270
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.